Pharmacokinetics of Omeprazole in Patients with Liver Cirrhosis and Extrahepatic Portal Venous Obstruction

R. Kumar, Y. K. Chawla, S. K. Garg, R. K. Dixit, Sanjaya Satapathy, R. K. Dhiman, V. K. Bhargava

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Omeprazole is frequently used in patients with cirrhosis of the liver to treat peptic ulcer disease. It is also used for the healing of mucosal lesions after endoscopic sclerotherapy of esophageal varices in cirrhosis and extraheptic portal vein obstruction (EHPVO). This study was carried out with the aim of determining the pharmacokinetics of omeprazole in different degrees of liver cirrhosis and in patients with EHPVO, compared with healthy volunteers. Ten healthy volunteers, 30 patients with cirrhosis of the liver, divided into 3 groups of 10 depending on severity (according to Child-Pugh classification A, B and C) and ten patients with EHPVO participated in the study. The subjects received an omeprazole 20 mg capsule after an overnight fast. Blood samples were collected at 0, 0.5, 1, 1.5, 2, 2.5, 3, 6, 9 and 24 h after drug administration. Omeprazole level in plasma was estimated by reverse-phase high performance liquid chromatography (HPLC). The elimination half-life was significantly (p < 0.05) increased to 2.38 ± 0.16, 3.26 ± 0.12, 3.58 ± 0.31 and 2.59 ± 0.22 h in patients with different grades of cirrhosis (A, B and C) and also in patients with EHPVO, respectively, compared with 1.054 + 0.10 h in healthy volunteers. A similar significant increase (p < 0.05) was observed in the AUC0-α, while C max was significantly increased to 400.40 ± 27.89 and 602 ± 55.13 ng/ml in only grade C cirrhosis patients and EHPVO patients, compared with 303.5 ± 36.42 ng/ml in healthy volunteers. No significant difference was observed in Tmax. It was concluded that the metabolism of omeprazole was significantly impaired in both liver cirrhosis and EHPVO in comparison with healthy volunteers.

Original languageEnglish (US)
Pages (from-to)625-630
Number of pages6
JournalMethods and Findings in Experimental and Clinical Pharmacology
Volume25
Issue number8
DOIs
StatePublished - Oct 1 2003

Fingerprint

Omeprazole
Liver Cirrhosis
Pharmacokinetics
Portal Vein
Healthy Volunteers
Fibrosis
Sclerotherapy
Esophageal and Gastric Varices
Reverse-Phase Chromatography
Peptic Ulcer
Capsules
Half-Life
High Pressure Liquid Chromatography
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacokinetics of Omeprazole in Patients with Liver Cirrhosis and Extrahepatic Portal Venous Obstruction. / Kumar, R.; Chawla, Y. K.; Garg, S. K.; Dixit, R. K.; Satapathy, Sanjaya; Dhiman, R. K.; Bhargava, V. K.

In: Methods and Findings in Experimental and Clinical Pharmacology, Vol. 25, No. 8, 01.10.2003, p. 625-630.

Research output: Contribution to journalArticle

Kumar, R. ; Chawla, Y. K. ; Garg, S. K. ; Dixit, R. K. ; Satapathy, Sanjaya ; Dhiman, R. K. ; Bhargava, V. K. / Pharmacokinetics of Omeprazole in Patients with Liver Cirrhosis and Extrahepatic Portal Venous Obstruction. In: Methods and Findings in Experimental and Clinical Pharmacology. 2003 ; Vol. 25, No. 8. pp. 625-630.
@article{d4b35bd6607d43c09213ed5ad69bcf32,
title = "Pharmacokinetics of Omeprazole in Patients with Liver Cirrhosis and Extrahepatic Portal Venous Obstruction",
abstract = "Omeprazole is frequently used in patients with cirrhosis of the liver to treat peptic ulcer disease. It is also used for the healing of mucosal lesions after endoscopic sclerotherapy of esophageal varices in cirrhosis and extraheptic portal vein obstruction (EHPVO). This study was carried out with the aim of determining the pharmacokinetics of omeprazole in different degrees of liver cirrhosis and in patients with EHPVO, compared with healthy volunteers. Ten healthy volunteers, 30 patients with cirrhosis of the liver, divided into 3 groups of 10 depending on severity (according to Child-Pugh classification A, B and C) and ten patients with EHPVO participated in the study. The subjects received an omeprazole 20 mg capsule after an overnight fast. Blood samples were collected at 0, 0.5, 1, 1.5, 2, 2.5, 3, 6, 9 and 24 h after drug administration. Omeprazole level in plasma was estimated by reverse-phase high performance liquid chromatography (HPLC). The elimination half-life was significantly (p < 0.05) increased to 2.38 ± 0.16, 3.26 ± 0.12, 3.58 ± 0.31 and 2.59 ± 0.22 h in patients with different grades of cirrhosis (A, B and C) and also in patients with EHPVO, respectively, compared with 1.054 + 0.10 h in healthy volunteers. A similar significant increase (p < 0.05) was observed in the AUC0-α, while C max was significantly increased to 400.40 ± 27.89 and 602 ± 55.13 ng/ml in only grade C cirrhosis patients and EHPVO patients, compared with 303.5 ± 36.42 ng/ml in healthy volunteers. No significant difference was observed in Tmax. It was concluded that the metabolism of omeprazole was significantly impaired in both liver cirrhosis and EHPVO in comparison with healthy volunteers.",
author = "R. Kumar and Chawla, {Y. K.} and Garg, {S. K.} and Dixit, {R. K.} and Sanjaya Satapathy and Dhiman, {R. K.} and Bhargava, {V. K.}",
year = "2003",
month = "10",
day = "1",
doi = "10.1358/mf.2003.25.8.778083",
language = "English (US)",
volume = "25",
pages = "625--630",
journal = "Methods and Findings in Experimental and Clinical Pharmacology",
issn = "0379-0355",
publisher = "Prous Science",
number = "8",

}

TY - JOUR

T1 - Pharmacokinetics of Omeprazole in Patients with Liver Cirrhosis and Extrahepatic Portal Venous Obstruction

AU - Kumar, R.

AU - Chawla, Y. K.

AU - Garg, S. K.

AU - Dixit, R. K.

AU - Satapathy, Sanjaya

AU - Dhiman, R. K.

AU - Bhargava, V. K.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Omeprazole is frequently used in patients with cirrhosis of the liver to treat peptic ulcer disease. It is also used for the healing of mucosal lesions after endoscopic sclerotherapy of esophageal varices in cirrhosis and extraheptic portal vein obstruction (EHPVO). This study was carried out with the aim of determining the pharmacokinetics of omeprazole in different degrees of liver cirrhosis and in patients with EHPVO, compared with healthy volunteers. Ten healthy volunteers, 30 patients with cirrhosis of the liver, divided into 3 groups of 10 depending on severity (according to Child-Pugh classification A, B and C) and ten patients with EHPVO participated in the study. The subjects received an omeprazole 20 mg capsule after an overnight fast. Blood samples were collected at 0, 0.5, 1, 1.5, 2, 2.5, 3, 6, 9 and 24 h after drug administration. Omeprazole level in plasma was estimated by reverse-phase high performance liquid chromatography (HPLC). The elimination half-life was significantly (p < 0.05) increased to 2.38 ± 0.16, 3.26 ± 0.12, 3.58 ± 0.31 and 2.59 ± 0.22 h in patients with different grades of cirrhosis (A, B and C) and also in patients with EHPVO, respectively, compared with 1.054 + 0.10 h in healthy volunteers. A similar significant increase (p < 0.05) was observed in the AUC0-α, while C max was significantly increased to 400.40 ± 27.89 and 602 ± 55.13 ng/ml in only grade C cirrhosis patients and EHPVO patients, compared with 303.5 ± 36.42 ng/ml in healthy volunteers. No significant difference was observed in Tmax. It was concluded that the metabolism of omeprazole was significantly impaired in both liver cirrhosis and EHPVO in comparison with healthy volunteers.

AB - Omeprazole is frequently used in patients with cirrhosis of the liver to treat peptic ulcer disease. It is also used for the healing of mucosal lesions after endoscopic sclerotherapy of esophageal varices in cirrhosis and extraheptic portal vein obstruction (EHPVO). This study was carried out with the aim of determining the pharmacokinetics of omeprazole in different degrees of liver cirrhosis and in patients with EHPVO, compared with healthy volunteers. Ten healthy volunteers, 30 patients with cirrhosis of the liver, divided into 3 groups of 10 depending on severity (according to Child-Pugh classification A, B and C) and ten patients with EHPVO participated in the study. The subjects received an omeprazole 20 mg capsule after an overnight fast. Blood samples were collected at 0, 0.5, 1, 1.5, 2, 2.5, 3, 6, 9 and 24 h after drug administration. Omeprazole level in plasma was estimated by reverse-phase high performance liquid chromatography (HPLC). The elimination half-life was significantly (p < 0.05) increased to 2.38 ± 0.16, 3.26 ± 0.12, 3.58 ± 0.31 and 2.59 ± 0.22 h in patients with different grades of cirrhosis (A, B and C) and also in patients with EHPVO, respectively, compared with 1.054 + 0.10 h in healthy volunteers. A similar significant increase (p < 0.05) was observed in the AUC0-α, while C max was significantly increased to 400.40 ± 27.89 and 602 ± 55.13 ng/ml in only grade C cirrhosis patients and EHPVO patients, compared with 303.5 ± 36.42 ng/ml in healthy volunteers. No significant difference was observed in Tmax. It was concluded that the metabolism of omeprazole was significantly impaired in both liver cirrhosis and EHPVO in comparison with healthy volunteers.

UR - http://www.scopus.com/inward/record.url?scp=0344065603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344065603&partnerID=8YFLogxK

U2 - 10.1358/mf.2003.25.8.778083

DO - 10.1358/mf.2003.25.8.778083

M3 - Article

VL - 25

SP - 625

EP - 630

JO - Methods and Findings in Experimental and Clinical Pharmacology

JF - Methods and Findings in Experimental and Clinical Pharmacology

SN - 0379-0355

IS - 8

ER -